0000000000811558

AUTHOR

Nathan P. Clark

showing 4 related works from this author

Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study.

2009

summaryKnowledge on the natural history of mesenteric vein thrombosis (MVT) and of the efficacy and safety of long-term oral anticoagulant therapy (OAT) in this setting is based on small uncontrolled series of patients with a limited follow-up. It was the aim of the study to assess the natural history of MVT in a cohort of patients treated with OAT. The charts of all MVT patients currently attending or who have attended four anticoagulation clinics were reviewed. Information on risk factors, treatment, recurrence, major bleeding and mortality was collected. Seventyseven patients (mean age 49.2 years; 45 males) were included with a median follow-up of 36 months (range 2–204 months). Forty-si…

AdultMaleRiskmedicine.medical_specialtyVitamin Kmedicine.drug_classmedicine.medical_treatmentSettore MED/15 - Malattie Del SangueCohort StudiesRisk FactorsmedicineHumansVeinAgedRetrospective StudiesAged 80 and overVenous ThrombosisChemotherapybusiness.industryAnticoagulantAnticoagulantsRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurgeryMesenteric ArteriesNatural historyVenous thrombosismedicine.anatomical_structuremesenteric vein thrombosisCohortFemalebusinessCohort study
researchProduct

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: A randomized trial

2009

BACKGROUND: Low-dose oral vitamin K decreases the international normalized ratio (INR) in overanticoagulated patients who receive warfarin therapy. Its effects on bleeding events are uncertain. OBJECTIVE: To see whether low-dose oral vitamin K reduces bleeding events over 90 days in patients with warfarin-associated coagulopathy. DESIGN: Multicenter, randomized, placebo-controlled trial. Randomization was computer-generated, and participants were allocated to trial groups by using sequentially numbered study drug containers. Patients, caregivers, and those who assessed outcomes were blinded to treatment assignment. SETTING: 14 anticoagulant therapy clinics in Canada, the United States, and …

Malemedicine.medical_specialtyRandomizationVitamin Kmedicine.drug_classAdministration OralHemorrhageoral vitamin k anticoagulantsPlacebolaw.inventionSettore MED/15 - Malattie Del SanguePlacebosRandomized controlled trialOral administrationlawInternal medicineThromboembolismInternal MedicinemedicineOutpatient clinicHumansInternational Normalized RatioAgedAged 80 and overbusiness.industryAnticoagulantWarfarinAge FactorsAnticoagulantsGeneral MedicineMiddle AgedAntifibrinolytic AgentsSurgeryClinical trialTreatment OutcomeFemaleWarfarinbusinessmedicine.drug
researchProduct

Natural History of Mesenteric Venous Thrombosis: A Large Multicentre Study

2008

Abstract Introduction: Mesenteric venous thrombosis (MVT) is an uncommon but potentially life-threatening disease, accounting for 5–15% of mesenteric ischemic events. Most cases of MVT are either identified at laparotomy or at autopsy, with a mortality rate of approximately 50% in old series. Advances in imaging techniques have facilitated the early diagnosis of MVT and, thus, have contributed to a decrease in mortality in the more recent series. The treatment of MVT involves anticoagulation alone or in combination with surgery. Experts suggest that MVT can safely be managed without surgery if there is no evidence of bowel infarction. However, information on the natural history of MVT and o…

medicine.medical_specialtyBowel infarctionbusiness.industryMortality ratemedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryThrombosisSurgeryNatural historymedicine.anatomical_structureSplanchnic vein thrombosisMedian follow-upLaparotomymedicineVeinbusinessBlood
researchProduct

Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10

2009

SummaryUnanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

Malemedicine.medical_specialtyVitamin Kmedicine.drug_classAdministration OralHemorrhagePharmacotherapyInternal medicinemedicineCoagulopathyHumansInternational Normalized RatioProspective StudiesProspective cohort studyAgedAged 80 and overVenous ThrombosisVascular diseasebusiness.industryAnticoagulantWarfarinAnticoagulantsHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryFemaleINR oral anticoagulantsWarfarinbusinessFollow-Up Studiesmedicine.drugCohort studyThrombosis and Haemostasis
researchProduct